Search PubMed⌕ Search

Biomedical subjects

I Adachi

Publications and source records attributed to I Adachi.

At least 217 records · Page 12Linked to original sources
PubMed1989

[Role of supporting therapy of Juzentaiho-to (JTT) in advanced breast cancer patients].

The patients were randomized with the envelope method, dividing into either A- or B-group. A-group was treated with JTT combined with chemoendocrine therapy. B-group was treated with only chemo-endocrine therapy. Between May 1985 and December 1987, 130 pts were used for this trial, 119 pts were evaluable, and 58 pts belonged to A-group and 61 to B-group. The pts characteristics were well balanced in both those groups. There was no significant difference in the response rates between A- and B-groups. The survival rate up to 38 months was not significantly different between the two groups, but in JTT-SHO group, the survival was significantly higher in the pts belonging to the A-group (Greenwood, p less than 0.05). The quality of life (QOL) was expressed as self-assessment scores for physical condition, appetite and the coldness of extremities. It improved significantly in A-group, especially, by prevention of bone marrow suppression by chemotherapy. It was concluded that treatment with JTT is better than without JTT in treatment for advanced breast cancer patients.

Adult↗
PubMed1989

Efficacy of coronary artery bypass surgery with gastroepiploic artery. Assessment with thallium 201 myocardial scintigraphy.

This study describes the efficacy of the right gastroepiploic artery (GEA) as graft material for coronary artery bypass grafting (CABG) as assessed by exercise thallium 201 myocardial scintigraphy in eight patients (age, 59.4 +/- 9.35 years [mean +/- SD]) who underwent CABG with the GEA graft in the past 2 years. Planar and single-photon-emission computed tomographic (SPECT) images were obtained during and 3 hours after exercise. Planar images were evaluated quantitatively with the percentile-washout method, and SPECT images were evaluated qualitatively with a bull's-eye, polar-coordinate map. All patients had triple-vessel disease, and in situ GEAs were anastomosed to the right coronary artery in seven patients and to the left anterior descending coronary artery in one. The internal mammary artery graft was concomitantly used in all patients. The mean number of grafts per patient was 3.0 (range, 2-4). Preoperative exercise testing could not be performed in two patients because of emergency operation. By qualitative assessment with the polar-coordinate map, four patients showed improvement, one did not show any change, and one became worse due to perioperative myocardial infarction.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1988

Expression of parathyroid hormone-related protein mRNA in tumors obtained from patients with humoral hypercalcemia of malignancy.

Human parathyroid hormone-related protein (PTHrP) mRNA was detected in all fresh cancer tissues consecutively obtained from 6 patients with humoral hypercalcemia of malignancy (HHM). The primary sites of the cancers in these cases were distributed among different organs including the lung, esophagus, kidney and ovary. PTHrP mRNA was undetectable in all 10 fresh cancer tissues obtained from normocalcemic patients. These results suggest PTHrP as a major cause of HHM.

Adult↗
PubMed1988

[Advanced sequelae of apical hypertrophic cardiomyopathy: report of two cases with wall motion abnormalities].

In view of the paucity of reports describing symptoms of increased degree, and deterioration of left ventricular systolic function in patients with apical hypertrophic cardiomyopathy (apical HCM), two cases with congestive heart failure and progressive thinning of previously hypertrophied apical portions of the left ventricle are reported. These were among 13 patients observed from eight to 10 years. Case 1: A 56-year-old man was diagnosed as having apical HCM at the age of 49 years. Severe left ventricular hypertrophy and prominent ST-T changes were observed on ECG during his first admission. His left ventricular end-diastolic pressure (LVEDP) was 24 mmHg and a left ventriculo-gram revealed a decrease in the left ventricular cavity in the apex and marked hypertrophy of the apical wall. Moderate interstitial fibrosis without hypertrophy or disarray of myocytes was observed in a left ventricular endomyocardial biopsy specimen. In two episodes of cardiac arrest he was successfully resuscitated at the age of 50 years. At the age of 55 years, two-dimensional echocardiography revealed thinning and abnormal motion in the apical wall, and a defect in 201T1 accumulation was observed in the same region by perfusion scintigraphy. This patient was readmitted with a diagnosis of cerebral embolism at the age of 56 years. Cardiac catheterization revealed normal LVEDP (8 mmHg), and a left ventriculogram revealed an aneurysm in the left ventricular apex with normal major epicardial coronary arteries. He has been under treatment with antiarrhythmic medications, calcium antagonists and anticoagulants, and has become relatively asymptomatic. Case 2: A 69-year-old-man was diagnosed as having apical HCM after a complete evaluation, including cardiac catheterization, at the age of 59 years. His LVEDP was elevated (17 mmHg), and a left ventricular angiogram revealed marked hypertrophy localized to the apex. Ejection fraction was 64%. A left ventricular endomyocardial biopsy revealed interstitial fibrosis without hypertrophy of myocytes. Thereafter, he has been followed as a New York Heart Association functional class III to IV with occasional elevation of cardiac enzymes but without chest pain or acute changes in his ECGs. However, atrial fibrillation with complete right bundle branch block developed at the age of 60 years. Apical wall thinning and dyskinesis were diagnosed by 2D echocardiography and a defect in the 201T1 accumulation was observed at about 65 years of age. He was readmitted in severe cardiac failure at the age of 69 years, and he was diagnosed as having cardiac asthma with pulmonary capillary wedge pressure of 35 mmHg.(ABSTRACT TRUNCATED AT 400 WORDS)

Aged↗
PubMed1987

[Bone metastasis in advanced breast cancer].

UNLABELLED: A retrospective analysis was performed comparing the survival in 483 patients with advanced breast cancer during the period from 1962 to 1986. RESULTS: Initial bone metastasis was found in 22%, and in 77% during course. The sites of bone metastasis were found more frequent in lumbar, thoracic, pelvis, rib, extremity and skull. Complications required with bone metastases were found in 19% of hypercalcemia which serum calcium level was more than 11 mg/dl, 14% of bone fracture, 10% sever spinal cord compression. Each complications caused by bone metastases had influence on the quality of life, but it had not effect on the patients survivals. Multidisciplinary treatment has been utilized as systemic therapy, such as combined chemoendocrine therapy. As local intensive therapy, the patients were treated with irradiation or surgical therapy. The patients with hypercalcemia were treated with calcitonin and mithramycin. Those treatments were useful for the prolongation of survival and the improvement of quality. As a result of those therapies, recently, the survival has been significantly prolonged. Especially, the survival in effective cases with those treatments was prolonged than the uncontrolled groups.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1987

Detection of gastrin-releasing peptide mRNA in small cell lung carcinomas and medullary thyroid carcinomas using synthetic oligodeoxyribonucleotide probes.

Human gastrin-releasing peptide (GRP) mRNA was detected in the tumor tissues of medullary thyroid carcinomas and small cell lung carcinomas using synthetic oligodeoxyribonucleotides as hybridization probes. The amount of GRP mRNA was estimated by radiodensitometric hybridization assay. A good correlation was found between the amount of GRP mRNA and the concentration of immunoreactive GRP in the tumor tissues.

Carcinoma↗
PubMed1987

[Recent advances in the treatment of advanced breast cancer: therapeutic modalities at the National Cancer Center Hospital].

A retrospective analysis was performed comparing the survival in 483 patients with advanced breast cancer during the period from 1962 to 1986. Recently, the five-year survival rate at the start of therapy to the primary tumor was 63% and the five-year survival rate after the recurrence was 25%. The survival has been significantly prolonged as opposed to the figure of less than 5% among patients of 15 years ago. Multidisciplinary treatment has been utilized as adjuvant and recurrent therapies, such as combined chemotherapy, chemo-endocrine therapy and irradiation. Within these patients, 13 cases (3%) survived for more than ten-years from recurrence. The patients were recurrent cases with a small amount of metastatic sites and responsive to long-term endocrine therapy.

Adult↗
PubMed1986

Characterization of histamine release in digitonin-permeabilized rabbit platelets.

To manipulate the intracellular milieu of rabbit platelets, permeabilization was performed using digitonin. Permeabilized platelets showed dose-dependent release of histamine, which was stored in granules of rabbit platelets, in response to extracellular calcium ion. As PMA stimulated the release reaction in digitonin-permeabilized platelets, the protein kinase C system, which regulates metabolic processes and cell reactions in intact platelets, was revealed to be working. Cupric phenanthroline also released histamine from permeabilized rabbit platelets dose-dependently, and dithiothreitol inhibited the release strongly. Since cupric phenanthroline is a mild oxidant which catalyzes the formation of disulfide bridges, as in the case of Ca2+-ATPase of sarcoplasmic reticulum, the results suggested that protein cross-linking is implicated in the regulation of the release reaction in permeabilized rabbit platelets.

Adenosine Triphosphate↗
PubMed1986

EL-4 tumor cell-induced human and rabbit platelet aggregations.

EL-4 tumor cells were assayed in vitro for their ability to aggregate two kinds of platelets. An inhibition study showed that the EL-4 tumor cell can induce platelet aggregation by at least two different mechanisms. One, mediated by thrombin, was dominant with rabbit platelets because hirudin, which specifically inhibits thrombin, considerably suppressed the rabbit platelet aggregation induced by EL-4 tumor cells. In contrast, EL-4 cells induced the aggregation of human platelets even in citrated PRP. It is the apyrase-sensitive pathway that is believed to work in human platelets. The human platelet responses to EL-4 tumor cells clearly differed from those of rabbit platelets in terms of inhibition by hirudin and apyrase and of reactivity in citrated PRP. Both phospholipase A2 and dibutyryl cAMP strongly inhibited EL-4 tumor cell-induced platelet aggregation in both rabbit and human platelets. These two compounds may block a vital step in platelet aggregation that is elicited by the EL-4 tumor cells. Our results show that human platelet response to tumor cells is not necessarily deducible from experimental data obtained with animal platelets.

Animals↗
PubMed1986

Heparin-induced leukocyte lysis in vitro.

An investigation on the effect of heparin on leukocytes in vitro was conducted. We have demonstrated that heparin and other mucopolysaccharides destroyed leukocytes as judged by macromolecule leakage. The cytotoxicity of heparin was suppressed by protamine. A medium which mimics intracellular ionic conditions was found to suppress the cytotoxicity of heparin. Macromolecule leakage induced by heparin is thought to be facilitated by passive ion flux. Mepacrine, a phospholipase inhibitor, suppressed the heparin-induced macromolecule leakage from leukocytes. Thus, the activation of phospholipase appears to be involved in the cytotoxicity of heparin. These results suggest that activation of phospholipase and passive movement of ions may be important steps for the heparin-induced leukocyte lysis in vitro.

Animals↗
PubMed1986

A retrospective evaluation of the medical treatment of malignancy-associated hypercalcemia.

Little is known about the relative effectiveness and potency of a variety of treatments for malignancy-associated hypercalcemia, or how beneficial the reversal of hypercalcemia is to these patients. Therefore, 146 trials of treatment for hypercalcemia between 1980 and 1983 at the National Cancer Center Hospital, Tokyo, were evaluated retrospectively. Serum calcium levels exhibited the largest decrease in the mithramycin-treated group (decrease; 5.4 +/- 1.8 mg/dl, mean +/- SD, n = 22), followed by the groups given calcitonin plus glucocorticoids (3.1 +/- 2.3, n = 11), glucocorticoids (2.3 +/- 2.3, n = 18), calcitonin (1.8 +/- 1.6, n = 51), hydration (1.3 +/- 2.5, n = 27), and indomethacin (1.0 +/- 2.3, n = 17). The effective rate was the highest with mithramycin (100%) and then with calcitonin plus glucocorticoids (73%) and with glucocorticoids (61%); it was less than 50% in the other modalities of treatment. In patients with pretreatment serum calcium levels of 14 mg/dl or more, the survival rate improved significantly in those whose serum calcium levels decreased below 12 mg/dl compared with those whose serum calcium remained above 12 mg/dl (50% survival; 35 vs. 9 days, P less than 0.01). These data provide a good guideline and a rationale in choosing the modality of treatment. In addition, the data show that the gain in the survival time achieved by successful treatment of hypercalcemia is clinically significant, because it is long enough to conduct additional antitumor therapy.

Adult↗